Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...
The Financial Express on MSN6mon
Health Canada gives nod to Lupin’s biosimilar to treat infection in cancer patientsThis product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech facility in Pune, India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback